Celltrion, Inc. reported second-quarter revenue of ₩1,393.7bn, up 45% year on year, and operating income of ₩451.8bn, a 32.4% margin, both records for a second quarter.
Celltrion's cost of revenue fell 9.6% in FY2025 while revenue grew 17.0%, an outcome no volume or pricing story can produce on its own.
Celltrion's retained earnings fell about ₩1.3tn in the second quarter of 2026 despite ₩371.3bn of profit, which points to roughly ₩1.5tn of share cancellation.
Celltrion terminated the European arm of its Keytruda biosimilar Phase 3 on 14 July 2026 and withdrew the trial plan, citing a changed global regulatory environment.
| Symbol | Last Price |
|---|---|
| 207940Samsung Biologics Co., Ltd. | ₩1,447,000 -2.0% |
| 196170Alteogen Inc. | ₩288,500 +1.9% |
| 326030SK biopharmaceuticals Co., Ltd. | ₩86,600 +0.2% |
| 128940Hanmi Pharm. Co., Ltd. | ₩473,500 +2.8% |
| 000100Yuhan Corporation | ₩81,400 +0.0% |
| 028300HLB Co., Ltd. | ₩33,750 +2.9% |
| 298380ABL Bio Inc. | ₩71,400 +5.6% |
| 000250Samchundang Pharm | ₩157,000 +1.0% |
| 087010Peptron, Inc. | ₩157,300 +7.3% |
| 141080LigaChem Biosciences Inc. | ₩92,000 +4.2% |